Skip to main content
. 2021 Jul 21;36(1):138–154. doi: 10.1038/s41375-021-01301-6

Fig. 8. Impact of inhibition of LAG3 ligands on proliferation and antitumor activities of MM-specific CTL.

Fig. 8

The role of the LAG3 ligands was analyzed using XBP1/CD138/CS1-specific CD8+ CTL against MM cells. A GAL-3 and HLA-DP/DQ/DR are both expressed in CD138+ tumor cells of MM cell lines (N = 3), with higher (*p < 0.05) intracellular than cell surface expression of GAL-3. B HLA-A2+ XBP1/CD138/CS1-specific CTL (N = 5) demonstrated increased MM-specific CD8+ CTL proliferation in response to HLA-A2+ U266 MM cells treated with anti-GAL-3, but not with anti-HLA-DP/DQ/DR, in a dose (U266 cells)-dependent manner (XBP1/CD138/CS1-CTL: MM cells = 1:1 > 1:0.5 > 1:0.25). C Proliferation of LAG+ cells was triggered in XBP1/CD138/CS1-specific CTL by stimulation with U266 treated with anti-GAL-3, but not with anti-HLA-DP/DQ/DR, in a dose (U266)-dependent manner (XBP1/CD138/CS1-CTL: MM cells = 1:1 > 1:0.5 > 1:0.25 > 1:0).